RTTNews | Jun 16, 2021 05:42PM EDT

17:42 Wednesday, June 16, 2021 (RTTNews.com) - Shares of biotechnology company CureVac NV (CVAC) are down 50 percent on Wednesday's after-trade after the company said that its trial COVID-19 vaccine showed an efficacy of 47% against the illness.

The company's vaccine CVAC, -3.47% messenger RNA-based vaccine, has shown lesser progress compared to other vaccines from Pfizer, BioNTech and Moderna.

The stock is trading at $47.14, down $47.59 or 50% in after-trade. CVAC ended Wednesday's trade at $94.79, down $3.41 or 3% on the NASDAQ.

Read the original article on RTTNews ( https://www.rttnews.com/3202916/stock-alert-curevac-drops-50.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved